Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) (Hematology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thrombotic Thrombocytopenic Purpura – Drugs In Development, 2021, provides an overview of the Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline landscape.Thrombotic Thrombocytopenic Purpura (TTP) is a rare blood disorder characterized by clotting in small blood vessels of the body (thromboses), resulting in a low platelet count. Symptoms include bleeding into the skin or mucus membranes, confusion, fever, headache, heart rate, shortness of breath, speech changes, weakness and yellowish color to the skin (jaundice). Treatment includes surgery to remove spleen and drugs that suppress the immune system, such as corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thrombotic Thrombocytopenic Purpura – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 1, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders).

– The pipeline guide reviews pipeline therapeutics for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Thrombotic Thrombocytopenic Purpura (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

KM Biologics Co Ltd

Lee's Pharmaceutical Holdings Ltd

PlateletBio

Sanofi

TagCyx Biotechnologies

Takeda Pharmaceutical Co Ltd

TargED Biopharmaceuticals BV

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Overview

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Companies Involved in Therapeutics Development

KM Biologics Co Ltd

Lee's Pharmaceutical Holdings Ltd

PlateletBio

Sanofi

TagCyx Biotechnologies

Takeda Pharmaceutical Co Ltd

TargED Biopharmaceuticals BV

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Drug Profiles

apadamtase alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

caplacizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Thrombotic Thrombocytopenic Purpura - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate ADAMTS13 for Thrombotic Thrombocytopenic Purpura - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Microlyse - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant ADAMTS-13 Replacement for Thrombotic Thrombocytopenic Purpura - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAGX-0004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZK-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Dormant Projects

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Discontinued Products

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Product Development Milestones

Featured News & Press Releases

Jun 10, 2021: Lee’s Pharm announces results of phase I clinical trial on the safety and antithrombotic efficacy of ANFIBATIDE

Sep 21, 2018: A Trojan Horse delivery of possible treatment for a rare, potentially deadly, blood-clotting disorder

Sep 14, 2017: Engineered Therapy for Blood Clotting Disorder Shows Early Promise

Mar 22, 2017: Shire receives FDA Fast Track designation for recombinant ADAMTS13 (SHP655) for treatment of hereditary thrombotic thrombocytopenic purpura

May 25, 2016: Baxalta Reports Positive Phase 1 Results for BAX 930, Investigational Recombinant ADAMTS13 to Treat Hereditary Thrombotic Thrombocytopenic Purpura

Mar 24, 2016: U.S. FDA Grants Orphan Drug Designation to Anfibatide for Treatment of Thrombotic Thrombocytopenic Purpura

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Pipeline by KM Biologics Co Ltd, 2021

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Pipeline by Lee's Pharmaceutical Holdings Ltd, 2021

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Pipeline by PlateletBio, 2021

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Pipeline by Sanofi, 2021

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Pipeline by TagCyx Biotechnologies, 2021

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Pipeline by Takeda Pharmaceutical Co Ltd, 2021

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Pipeline by TargED Biopharmaceuticals BV, 2021

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Dormant Projects, 2021

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease), 2021

Number of Products under Development by Companies, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports